Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 1/20 | 0.49 |
| ▸ | SELP | P16109 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11462528 | 0.91 | MRGPRX4 (0.62) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL4086439 | 0.86 | ALDH1A1 (0.53) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL3616256 | 0.86 | ALDH1A1 (0.53) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL586214 | 0.86 | GAA (0.68) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL30154464 | 0.86 | GAA (0.68) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL27590527 | 0.85 | HSD17B10 (0.57) | GAAALDH1A1CA2SMN1; SMN2HSD17B10 | |
| SCHEMBL7896877 | 0.85 | ALDH1A1 (0.56) | GAAALDH1A1CA2SMN1; SMN2HSD17B10 | |
| SCHEMBL153055 | 0.84 | GAA (0.74) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL30049382 | 0.84 | GAA (0.74) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL23296176 | 0.84 | GAA (0.52) | GAAALDH1A1TSHRNFKB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145906-B1 | SEROTONIN RECEPTOR-TARGETING COMPOUNDS | UNIV NORTHEASTERN (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-106573872-B | 5-hydroxytryptamine receptor targeting compounds and methods | 东北大学 | 2021-07-20 | — | — | CN | disclosed |
| US-11021435-B2 | Serotonin receptor-targeting compounds and methods | NORTHEASTERN UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| CN-106573872-A | 5-hydroxytryptamine receptor targeting compounds and methods | 东北大学 | 2017-04-19 | — | — | CN | disclosed |
| EP-3145906-A1 | SEROTONIN RECEPTOR-TARGETING COMPOUNDS AND METHODS | Northeastern University (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| WO-2015179366-A1 | SEROTONIN RECEPTOR-TARGETING COMPOUNDS AND METHODS | NORTHEASTERN UNIVERSITY (US) | 2015-11-26 | — | — | WO | disclosed |
| CN-102775381-B | Substituted hydrazide compound, and its preparation method, medicinal compositions and application | SHANGHAI INST MATERIA MEDICA | 2015-05-20 | — | — | CN | disclosed |
| CN-102775381-A | Substituted hydrazide compound, and its preparation method, medicinal compositions and application | SHANGHAI INST MATERIA MEDICA | 2012-11-14 | — | — | CN | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5633272-A | Substituted isoxazoles for the treatment of inflammation | PHARMACIA & UPJOHN COMPANY LLC | 1997-05-27 | — | — | US | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | disclosed |
| CN-1124250-A | 17-deoxycorticosteroid-21-[O]-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1996-06-12 | — | — | CN | disclosed |
| EP-0708111-A1 | 17-Desoxy corticosteroid-21-esters, a process for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-24 | — | — | EP | disclosed |
| CN-1108661-A | Corticoid 17,21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1995-09-20 | — | — | CN | disclosed |
| CN-1105368-A | Corticosteroid 17-alkyl carbonate 21-[O]-carboxylic and carbonic esters, processes for their preparation, and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1995-07-19 | — | — | CN | disclosed |
| EP-0646593-A1 | Corticoid-17,21-dicarboxylic acid ester and corticosteroid-17-carboxylic acid ester-21-carbonic, process for their production and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0640616-A2 | 17-Alkylcarbonate, 21-0-carbonic/carboxylic acid esters of corticosteroids, a method for their production and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021435-B2 | Serotonin receptor-targeting compounds and methods | HTR1A, HTR2C, HTR7 | GAA 4506/4885ALDH1A1 2137/4885TSHR 327/4885 |
| US-20170081273-A1 | Serotonin Receptor-Targeting Compounds and Methods | HTR1A, HTR2C, HTR7 | GAA 4506/4885ALDH1A1 2137/4885TSHR 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.